Journey Medical Corporation (DERM)
DERM Stock Price Chart
Explore Journey Medical Corporation interactive price chart. Choose custom timeframes to analyze DERM price movements and trends.
DERM Company Profile
Discover essential business fundamentals and corporate details for Journey Medical Corporation (DERM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
12 Nov 2021
Employees
41.00
Website
https://journeymedicalcorp.comCEO
Claude Maraoui
Description
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
DERM Financial Timeline
Browse a chronological timeline of Journey Medical Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 Mar 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.03, while revenue estimate is $18.66M.
Earnings released on 12 Aug 2025
EPS came in at -$0.16 falling short of the estimated -$0.07 by -128.57%, while revenue for the quarter reached $15.01M , missing expectations by -20.60%.
Earnings released on 14 May 2025
EPS came in at -$0.18 surpassing the estimated -$0.24 by +25.00%, while revenue for the quarter reached $13.14M , missing expectations by -12.01%.
Earnings released on 26 Mar 2025
EPS came in at $0.08 surpassing the estimated -$0.22 by +136.36%, while revenue for the quarter reached $13.62M , beating expectations by +12.99%.
Earnings released on 12 Nov 2024
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached $14.63M , beating expectations by +2.93%.
Earnings released on 12 Aug 2024
EPS came in at -$0.17 falling short of the estimated -$0.15 by -13.33%, while revenue for the quarter reached $14.86M , beating expectations by +3.23%.
Earnings released on 13 May 2024
EPS came in at -$0.53 falling short of the estimated -$0.26 by -103.85%, while revenue for the quarter reached $13.03M , missing expectations by -7.62%.
Earnings released on 21 Mar 2024
EPS came in at -$0.12 falling short of the estimated -$0.08 by -50.00%, while revenue for the quarter reached $15.26M , beating expectations by +1.31%.
Earnings released on 7 Nov 2023
EPS came in at $0.80 surpassing the estimated -$0.15 by +633.33%, while revenue for the quarter reached $34.54M , beating expectations by +122.40%.
Earnings released on 8 Aug 2023
EPS came in at -$0.46 falling short of the estimated -$0.34 by -35.29%, while revenue for the quarter reached $17.17M , beating expectations by +13.27%.
Earnings released on 22 May 2023
EPS came in at -$0.57 falling short of the estimated -$0.44 by -29.55%, while revenue for the quarter reached $12.21M , missing expectations by -18.96%.
Earnings released on 29 Mar 2023
EPS came in at -$0.60 falling short of the estimated -$0.37 by -62.16%, while revenue for the quarter reached $15.97M , missing expectations by -1.32%.
Earnings released on 10 Nov 2022
EPS came in at -$0.57 falling short of the estimated -$0.34 by -67.65%, while revenue for the quarter reached $16.12M , missing expectations by -2.80%.
Earnings released on 9 Aug 2022
EPS came in at -$0.43 falling short of the estimated -$0.25 by -72.00%, while revenue for the quarter reached $18.29M , missing expectations by -14.13%.
Earnings released on 10 May 2022
EPS came in at -$0.08 surpassing the estimated -$0.18 by +55.56%, while revenue for the quarter reached $23.30M , beating expectations by +5.11%.
Earnings released on 23 Mar 2022
EPS came in at -$1.64 falling short of the estimated -$0.29 by -465.52%, while revenue for the quarter reached $17.52M , missing expectations by -14.08%.
Earnings released on 10 Dec 2021
EPS came in at -$1.16 falling short of the estimated -$0.87 by -33.57%, while revenue for the quarter reached $19.61M , beating expectations by +46.89%.
Earnings released on 12 Nov 2021
EPS came in at -$1.30 , while revenue for the quarter reached $15.29M .
Earnings released on 31 Mar 2021
EPS came in at $0.03 , while revenue for the quarter reached $10.72M .
Earnings released on 31 Dec 2020
EPS came in at $0.15 , while revenue for the quarter reached $13.72M .
Earnings released on 30 Sept 2020
EPS came in at $0.00 , while revenue for the quarter reached $9.45M .
DERM Stock Performance
Access detailed DERM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.